RNS Number : 4320Y
Genedrive PLC
12 October 2026

12 October 2026

genedrive plc
("genedrive" or the "Company")

NIHR case study highlights collaboration with genedrive on development of MT-RNR1 rapid genetic test

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, notes the publication of a new case study by the National Institute for Health and Care Research (NIHR) on the development, clinical validation and adoption of the Genedrive® MT-RNR1 ID Kit.

Published on 7 October 2026, the case study provides an overview of genedrive's collaboration with the NIHR, the University of Manchester and Manchester University NHS Foundation Trust in developing the world's first rapid point-of-care genetic test to identify newborns at risk of hearing loss from certain antibiotics. It outlines the role of NIHR funding and clinical research in supporting the technology's ongoing adoption, including the PALOH and follow-on PALOH-UK studies. It also highlights the potential for genedrive's technology to deliver an estimated £5 million in annual NHS savings, if rolled out nationally.

Dr Maria Koufali, Life Sciences Industry Director at the NIHR, commented: *"The genedrive story is exactly why the NIHR Industry Hub exists. We created a fast, navigable route for SMEs to turn outstanding science into trial-ready solutions and scalable clinical impact. Through partnership with the UK's integrated research system, genedrive has not only transformed neonatal care, but generated the robust clinical evidence required to unlock international scale and investment."*

Gino Miele, Chief Executive Officer of genedrive plc,: *"By joining forces with the NIHR, the Government's Office for Life Sciences, and leading clinicians, we are not only driving faster adoption within the NHS, but also enhancing patient outcomes and delivering measurable economic benefits to the healthcare system."*

The full NIHR case study is available at:
https://www.nihr.ac.uk/story/preventing-hearing-loss-newborns-rapid-genetic-testing

genedrive plc	+44 (0)161 989 0245
Gino Miele: CEO / Russ Shaw: CFO	https://investors.genedrive.com/s/e0025c
Peel Hunt LLP (Nominated Adviser and Broker)	+44 (0)20 7418 8900
James Steel	
5654 & Company (Media & Investor Relations)	genedrive@5654.co.uk
Matthew Neal	+44 (0)7917 800 011
Melissa Gardiner	+44 (0)7757 697357
Lucy Featherstone	+44 (0)7474 953578

Subscribe to our news alert service: https://investors.genedrive.com/s/efea03

About genedrive plc (http://www.genedrive.com).

genedrive plc is a UK-based, commercial-stage pharmacogenetic testing company focused on rapid, point-of-care diagnostic tests to guide safe and effective drug prescription in emergency and acute care settings.

genedrive's proprietary technology platform enables clinicians to prescribe safer and more effective therapies based on a patient's genetic profile, supporting improved outcomes while reducing pressure on healthcare systems, lowering downstream healthcare costs through the prevention of avoidable complications and earlier, more effective intervention

The Company has two CE-IVD approved and NICE-recommended tests in NHS clinical use. The Genedrive® CYP2C19 ID Kit identifies stroke patients who will not respond to the current standard of care, Clopidogrel, used to reduce risk of secondary stroke. The Genedrive® MT-RNR1 ID Kit helps prevent antibiotic-induced hearing loss (AIHL) in newborns, enabling treatment decisions within actionable timeframes at the point of care.

Headquartered in Manchester, genedrive is focused on scaling UK-developed precision diagnostics within routine care and leveraging real-world evidence to support broader international adoption and commercial growth.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAEAKENEFKKFFA